Recruiting
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.
ClinicalTrials.gov IDNCT06220721
PhaseNA
Enrollment618
SponsorMedical College of Wisconsin
Age18 Years
SexFEMALE
Conditions studied
Hypertension, Pregnancy-Induced
About this study
The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.
Interventions
- Drug: Nifedipine ER — Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.
Primary outcomes
- Chronic hypertension (One year postpartum)
Eligibility information
Inclusion Criteria:
* Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
* Postpartum day 0-4
* Age ≥ 18 years
* Able to communicate in English or in Spanish
* Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records.
Exclusion Criteria:
* Pre-gestational hypertension
* Type 1 or type 2 diabetes mellitus
* Admitted to intensive care unit at the time of screening
* Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization
* Getting discharged on the day of screening
* Known allergy or contraindication to nifedipine ER
* Inability or unwillingness to provide informed consent
* Already taking long-acting antihypertensive medication for standard care
* Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus
Study locations
- Northwestern University, Chicago, Illinois 60611 United States
- Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.